Cryopreservation protocols are increasingly required in regenerative medicine applications but must deliver functional products at clinical scale and comply with Good Manufacturing Process (GMP). While GMP cryopreservation is achievable on a small scale using a Stirling cryocooler-based controlled rate freezer (CRF) (EF600), successful large-scale GMP cryopreservation is more challenging due to heat transfer issues and control of ice nucleation, both complex events that impact success. We have developed a large-scale cryocooler-based CRF (VIA Freeze) that can process larger volumes and have evaluated it using alginate-encapsulated liver cell (HepG2) spheroids (ELS). It is anticipated that ELS will comprise the cellular component of a bioartificial liver and will be required in volumes of ~2 L for clinical use. Sample temperatures and Stirling cryocooler power consumption was recorded throughout cooling runs for both small (500 mL) and large (200 mL) volume samples. ELS recoveries were assessed using viability (FDA/PI staining with image analysis), cell number (nuclei count), and function (protein secretion), along with cryoscanning electron microscopy and freeze substitution techniques to identify possible injury mechanisms. Slow cooling profiles were successfully applied to samples in both the EF600 and the VIA Freeze, and a number of cooling and warming profiles were evaluated. An optimized cooling protocol with a nonlinear cooling profile from ice nucleation to −60°C was implemented in both the EF600 and VIA Freeze. In the VIA Freeze the nucleation of ice is detected by the control software, allowing both noninvasive detection of the nucleation event for quality control purposes and the potential to modify the cooling profile following ice nucleation in an active manner. When processing 200 mL of ELS in the VIA Freeze—viabilities at 93.4%–7.4%, viable cell numbers at 14.3–1.7 million nuclei/mL alginate, and protein secretion at 10.5–1.7 mg/mL/24 h were obtained which, compared well with control ELS (viability 98.1%–0.9%; viable cell numbers 18.3–1.0 million nuclei/mL alginate; and protein secretion 18.7–1.8 mg/mL/24 h). Large volume GMP cryopreservation of ELS is possible with good functional recovery using the VIA Freeze and may also be applied to other regenerative medicine applications.

Introduction

ONE BOTTLENECK IN manufacturing and clinical delivery of regenerative medicine is successful cryopreservation. The preservation of cells to current Good Manufacturing Process (cGMP) requires validated, reproducible, and safe methods. However, cryopreservation provides various challenges in this context. These include retention of good functionality, sterility, and scale up: for example, estimates for a bioartificial liver indicate that cryopreservation of 2 L of alginate-encapsulated cell spheroids (ELS) are required.2

Cryopreservation in bags of large volumes (>100 mL) of adult stem cells3 and of mammalian tissue culture cells4–6 using conventional liquid nitrogen-based controlled rate freezers (CRFs) is established. However, the use of liquid nitrogen is problematic in a GMP environment; following manufacture, liquid nitrogen contains very low levels of contaminants, but during transport and storage it can become contaminated by ice, inanimate debris, and viable microorganisms7–9 that can transfer to the local environment.7,10 It is possible to filter industrial quantities of liquid nitrogen to appropriate standards and the UV sterilization of liquid nitrogen has been proposed11; however,
unless liquid nitrogen is filtered or sterilized by validated methods it cannot be used in a clean room without compromising air quality. An alternative strategy, avoiding the requirement for nitrogen during cooling is the use of CRF based on electrically powered Stirling cryocoolers, which operate efficiently down to cryogenic temperatures. Equipment based on Stirling cryocoolers has been successfully used for controlled rate freezing of a range of cell types including human embryonic stem cells and ELS12,13 but this equipment is limited to processing to small volumes (<50 mL total).

In this study, we address the issues of scaling up small volume cryopreservation methods and the development of cryocooler-based equipment for the large volume GMP compatible process. Initially, a set of feasibility experiments was carried out in cryovials applying a range of cooling profiles to investigate the effects of the physical conditions and thermal histories anticipated during cryopreservation in large volumes. We also investigated control of ice nucleation during scale up, which is essential for high cell viability in large volumes. We also investigated control of ice nucleation during scale up, which is essential for high cell viability in many cryopreservation protocols.15 We also investigated final cell: cryoprotectant volume ratios, since it is desirable to reduce the overall sample volume as this determines heat transfer both during controlled slow cooling and rapid warming in large volumes.3 Finally, the large-scale Stirling cryocooler-based CRF (VIA Freeze) was used with ELS as a model system for equipment development and optimization.

Materials and Methods

Cell culture

HepG2 cells were obtained from the ECACC (Wiltshire, United Kingdom) and maintained in modified MEM-alpha medium (Gibco, Paisley, United Kingdom) supplemented with 10% FBS (Hyclone, Loughborough, United Kingdom), 100 IU/mL penicillin, and 0.1 mg/mL streptomycin. HepG2 cells were not used beyond passage 50.

The techniques of alginate encapsulation and culture to achieve competent ELS have been described previously. Alginate beads have an approximate diameter of 500 μm. HepG2 cell spheroids are not uniformly spherical but are typically irregular shaped.2,14 For small volume experiments, ELS were maintained in static culture for 7 days in six-well plates in media supplemented with glucose to a final concentration of 22.5 mM, with 10% FFP in place of FCS.2 For large volume experiments, ELS were maintained in culture for 11 days in a fluidized bed bioreactor. Fifty percent, 70%, and 80% media changes were performed on days 6, 8, and 10 respectively.2 For all experiments, cell density within ELS was ∼20 × 10^9/mL alginate. The exact cell densities within each set of experiments are given in Tables 1, 2, and 3 under “unfrozen control.” These cell densities represent the standard densities achieved following conditioning culture.

Cryopreservation

Cryoprotectants. ELS were cryopreserved in cryoprotectant (CPA) of 12% DMSO with 10% FFP15 in University of Wisconsin solution with 500 IU/mL catalase and 1.7 mM Trolox as antioxidants15 ±1 mg/mL crystalline cholesterol to act as a nucleant.16 Unless stated otherwise, the ratio of volumes of ELS to CPA in cryovials was 1:1 representing a cell density of ∼10^10/mL. In some experiments, once alginate beads had been transferred into cryovials and allowed to settle under gravity, the ratios of ELS to CPA were modified by removing supernatant CPA, to achieve ratios of 1:2/3, 1:1/3, and 1:0 (i.e., removal of all supernatant CPA). Controlled rate freezers. Feasibility experiments in cryovials: For feasibility experiments in small volumes, an E600 (Grant Instruments, Cambridge, United Kingdom) was used.17 Cryovials (375418; Nunc, Loughborough, United Kingdom) (capacity 1.8 mL) were loaded with 0.25 mL ELS equilibrated with 0.25 mL chilled (4°C) CPA prior to cooling.

Large volume experiments in cryobags: For large volume experiments, a VIA Freeze (Asymptote Ltd, Cambridge, United Kingdom) was used to cryopreserve ELS in cryobags (Fig. 1). In this device, cooling of a horizontal sample plate was achieved by two Stirling cryocoolers connected to a metal plate, directly onto which the cryobags were placed (cooling was achieved from one side of the bag only). The dimensions of the sample plate are 250 × 450 mm. The plate temperature and the voltage applied to the VIA Freeze were monitored and logged.

Table 1. Comparison of ELS Recovery at 24 h After Thawing Following Cryopreservation at Different ELS:CPA Ratios

<table>
<thead>
<tr>
<th>ELS:CPA ratio (cell density)</th>
<th>Viability (%)</th>
<th>Viable cell number (10^6 nuclei/mL alginate)</th>
<th>Total function (μg AFP/24 h)</th>
<th>Normalized function (μg AFP/10^6 nuclei/24 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unfrozen control (−)</td>
<td>98.0 ± 0.5</td>
<td>24.9 ± 2.1</td>
<td>17.9 ± 0.8</td>
<td>23.2 ± 1.7</td>
</tr>
<tr>
<td>1:1 (12.5 × 10^6/mL)</td>
<td>95.2 ± 2.2</td>
<td>21.0 ± 2.2</td>
<td>11.8 ± 1.1**</td>
<td>18.2 ± 2.1*</td>
</tr>
<tr>
<td>1:2/3 (15 × 10^6/mL)</td>
<td>95.4 ± 1.4***</td>
<td>19.9 ± 2.2*</td>
<td>11.6 ± 2.6***</td>
<td>18.5 ± 3.9</td>
</tr>
<tr>
<td>1:1/3 (18.75 × 10^6/mL)</td>
<td>96.2 ± 1.3</td>
<td>17.7 ± 1.3***</td>
<td>11.5 ± 1.4***</td>
<td>20.8 ± 2.0</td>
</tr>
<tr>
<td>1:0 (25 × 10^6/mL)</td>
<td>95.3 ± 1.6*</td>
<td>16.7 ± 1.8***</td>
<td>10.5 ± 1.7***~</td>
<td>20.2 ± 3.7</td>
</tr>
</tbody>
</table>

ELS were cooled in cryovials using the EF600. The rate of cooling was 1°C/min and cholesterol was used as ice nucleant in all samples. Each cryovial contained 250 μL of ELS but the volume of CPA was varied. Four different ratios of ELS:CPA were tested: 1:1 (i.e., 250 μL ELS, 250 μL CPA); 1:2/3; 1:1/3; and 1:0 (e.g., 250 μL ELS, 0 μL CPA). ELS recovery (viability, viable cell numbers, and function) 24 h after thawing was compared to unfrozen control. These data demonstrated that reducing the volume of CPA within the cryovial did not reduce ELS recovery. n = 5 ± SD, ⋆p < 0.05, **p < 0.01, ***p < 0.005 cf. unfrozen control. p < 0.05, **p < 0.01 cf. ELS cryopreserved at an ELS:CPA ratio of 1:1. ⋆p < 0.05 cf. ELS cryopreserved at an ELS:CPA ratio of 1:1/3. ELS, encapsulated cell spheroids; CPA, cryoprotectant.
ELS recovery (viability, viable cell numbers, and function) 24 h after thawing was compared to unfrozen control. These data demonstrate that ELS recovery in cryovials to cryobags did not differ when profiles A and B were applied during cooling, suggesting successful scale up of the cryopreservation protocol. For all runs the VIA Freeze was cooled to 8°C and held at this temperature while samples were prepared. ELS were cryopreserved in either cryovials (small volume) or cryobags (large volume) alongside each other. Three different cooling profiles (shown in Fig. 3) were used in cryovials in the EF600 to directly compare ELS recovery in cryovials to ELS recovery in cryobags. The first was a linear cooling rate of 1°C/min with a 10-min hold period at −8°C (just below the estimated temperature of ice nucleation in samples with ice nucleants) and a linear rate of cooling of 1°C/min.

### Table 2. Comparison of ELS Recovery at 24 h After Thawing Using Different Warming Rates

<table>
<thead>
<tr>
<th>Thawing method</th>
<th>Time taken to thaw (min)</th>
<th>Viability (%)</th>
<th>Viable cell number (10^6 nuclei/mL alginate)</th>
<th>Function (µg AFP/24 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unfrozen control</td>
<td>–</td>
<td>99.5 ± 0.6</td>
<td>17.7 ± 0.9</td>
<td>15.3 ± 2.8</td>
</tr>
<tr>
<td>37°C water</td>
<td>1.75 ± 0.5</td>
<td>97.8 ± 0.5***</td>
<td>14.4 ± 1.2**</td>
<td>8.7 ± 1.8*</td>
</tr>
<tr>
<td>20°C water</td>
<td>2.42 ± 0.5</td>
<td>93.2 ± 1.7***</td>
<td>14.1 ± 0.9**</td>
<td>7.5 ± 0.3**</td>
</tr>
<tr>
<td>20°C air</td>
<td>12.92 ± 0.2</td>
<td>92.7 ± 3.1***</td>
<td>9.3 ± 1.0***</td>
<td>6.5 ± 0.9***</td>
</tr>
<tr>
<td>4°C air</td>
<td>24.5 ± 4.7</td>
<td>90.9 ± 4.9***</td>
<td>8.3 ± 1.4***</td>
<td>5.8 ± 0.5***</td>
</tr>
</tbody>
</table>

ELS were cooled in cryovials using the EF600. The rate of cooling was 1°C/min and cholesterol was used as ice nucleant in all samples. Following cooling, the cryovials were warmed using four different methodologies: 37°C water; 20°C water; 20°C air; and 4°C water to obtain a range of warming rates. The times taken to thaw the cryovials using these four methodologies is given in column 2 (n = 2, mean ± range). ELS recovery (viability, viable cell numbers, and function) 24 h after thawing was compared to unfrozen control. These data demonstrate that ELS recovery is greatest when rapid warming rates are applied. n = 3 ± SD. *p < 0.05, **p < 0.01, ***p < 0.005 compared to unfrozen control. #p < 0.05, ##p < 0.01, ###p < 0.005 compared to ELS thawed in 37°C water. ^p < 0.01 compared to ELS thawed in 20°C water.

For all runs the VIA Freeze was cooled to +4°C and held at this temperature while samples were prepared. ELS were equilibrated with chilled (4°C) CPA and loaded into Cryo-MACS bags (200-074-404; Miltenyi Biotec Ltd, Glasgow, United Kingdom). Excess CPA was removed by rolling the cryobags so that only ~10 mL excess CPA remained (with ~190 mL ELS). Once loaded onto the VIA Freeze, the plate was held for a further 15 min to allow ELS and plate temperature equilibration before cooling. The cryobags were compressed by a styrofoam lid to achieve a uniform thickness (~4 mm).

### Cooling rates. Outcome assessments of cooling in cryovials for characterization and feasibility experiments: Five cooling profiles were examined in cryovials with ELS containing ~20 × 10^6 cells/mL alginate in the EF600. Three were programmed (Figs. 2A and 3) to characterize ELS recovery using different profiles down to −100°C:

1. A previously studied multi-step slow cooling profile16,18 designed to model cooling in cryobags were also tested in cryovials using the EF600 (Fig. 2A) These cooling rates applied an average cooling rate of 1°C/min between −8°C and −100°C, with specific but different nonlinear segments in the high subzero temperature range18:
   4. “Controlled concentration” profile
   5. “Constant change in ice fraction with time” profile

To discern whether or not ice nucleators were necessary during cryopreservation, ELS were cooled in cryovials with either cholesterol (an efficient ice nucleator)16 or with no nucleator.

### Table 3. Direct Comparison of ELS Recovery After Cryopreservation Using Three Different Cooling Profiles in Cryovials or Cryobags

<table>
<thead>
<tr>
<th></th>
<th>Viability (%)</th>
<th>Viable cell number (10^6 nuclei/mL alginate)</th>
<th>Function (µg AFP/mL/24 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unfrozen control</td>
<td>98.1 ± 0.9</td>
<td>18.3 ± 1.0</td>
<td>18.7 ± 1.8</td>
</tr>
<tr>
<td>Profile A (Fig. 3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryovial</td>
<td>82.8 ± 9.8</td>
<td>10.6 ± 0.5</td>
<td>11.7 ± 4.4</td>
</tr>
<tr>
<td>Cryobag</td>
<td>79.7 ± 13.0</td>
<td>10.0 ± 0.6</td>
<td>13.2 ± 1.2***</td>
</tr>
<tr>
<td>Profile B (Fig. 3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryovial</td>
<td>93.4 ± 7.4</td>
<td>14.3 ± 1.7</td>
<td>10.5 ± 1.7</td>
</tr>
<tr>
<td>Cryobag</td>
<td>85.9 ± 5.5</td>
<td>15.2 ± 1.7</td>
<td>12.0 ± 0.9</td>
</tr>
<tr>
<td>Profile C (Fig. 3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryovial</td>
<td>62.0 ± 10.8</td>
<td>6.4 ± 0.5</td>
<td>5.7 ± 0.6</td>
</tr>
<tr>
<td>Cryobag</td>
<td>77.2 ± 11.2</td>
<td>12.9 ± 1.8***</td>
<td>10.2 ± 0.8***</td>
</tr>
</tbody>
</table>

ELS were cryopreserved in either cryovials (small volume) or cryobags (large volume) alongside each other. Three different cooling profiles (shown in Fig. 3) were tested. Cholesterol was included as ice nucleant in each and the ELS: CPA ratio was 1:0. ELS recovery (viability, viable cell numbers, and function) 24 h after thawing was compared to unfrozen control. These results indicate that ELS recovery from cryovials and cryobags did not differ when profiles A and B were applied during cooling, suggesting successful scale up of the cryopreservation protocol. n = 5 ± SD. ***p < 0.005 compared to ELS cryopreserved in cryovials using the same cooling profile. "p < 0.05, ""p < 0.01 compared to ELS cryopreserved in cryobags using profile B. ^p < 0.05, ^^^p < 0.005 compared to ELS cryopreserved in cryobags using profile C.
Temperature measurements during cooling. T-type thermocouples connected to a Picolog TC-08 data logging device (PicoTechnology, St Neots, United Kingdom) were used to measure the temperatures of samples within bags and cryovials. When the ELS reached programmed end-temperatures, they were transferred to the vapor phase of liquid nitrogen for storage (>1 day).

Warming. Routinely, ELS in either cryovials or bags were removed from storage and transferred to a 37°C water bath until the last ice crystal had melted. Samples were then placed on ice, ELS allowed to settle under gravity, supernatant CPA removed, and washed using equal volumes of chilled culture medium. This was then removed and replaced with complete, prewarmed, culture medium.

To achieve different rates of rewarming in the feasibility studies, cryovials were warmed in +4°C air, +20°C air, or +20°C water. The times taken to thaw (when the last ice crystal melted) from nitrogen storage (−150°C) were recorded.

Ultrastructure of cryopreserved samples

Cryoscanning electron microscopy. Cryovials containing ELS were cooled using a linear cooling rate of −1°C/min in the EF600 and transferred to liquid nitrogen. Cryovials were fractured under liquid nitrogen and the frozen plug removed intact. The plug was fractured vertically down the mid plane under liquid nitrogen and then loaded onto the preparation stage of a FEI Philips XL30 FEGSEM (Quorum PPT 2000). The stage was warmed from −145°C to −95°C over 6 min and the sample etched at −95°C for 60 min before cooling to −145°C. The sample was then coated with 10–15 nm gold and loaded back onto the cryoscanning electron microscopy (CryoSEM) stage for image recording.

Freeze substitution. Some samples were refractured to make segments with a maximum dimension of 1 mm and then transferred under liquid nitrogen to automated freeze substitution chambers (Reichert; Leica, Vienna, Austria). The substitution medium contained 2% osmium tetroxide and 1% uranyl acetate in methyl alcohol as contrast agents. Samples were maintained at −90°C for 24 h, warmed to −70°C at 3°C/h, and then maintained at −70°C for 24 h. Afterward
they were warmed to room temperature at $$+3^\circ \text{C}/\text{h}$$, rinsed in methyl alcohol, and embedded in Spurr’s epoxy resin. Sections were cut at 0.5 μm thickness with a Reichert Ultracut S and stained with methylene blue for preliminary inspection and orientation.

**Cell viability and function following freezing and thawing**

For small volume experiments in cryovials in the EF600, ELS were returned to static culture in six-well plates following cryopreservation. For large volume experiments in the Via Freeze, ELS were returned to culture in a rotating cell culture system,14 which mimics the cell culture conditions of the large-scale fluidized bed bioreactor used to culture ELS prior to cryopreservation.

The methods used to assess recovery at 24 h post-warming are described elsewhere.16 (This particular time point post-warming was chosen as this represents the time at which ELS viability would be lowest, before they begin to recover.) Briefly, ELS were stained using fluorescein diacetate and propidium iodide and viabilities were quantified using image analysis.16 Cell numbers were measured by releasing spheroids from alginate using 16 mM EDTA/0.15 M NaCl (pH 7.4) and nuclei count using the Nucleo-counter system. Function was assessed by measuring total α1-fetoprotein release in the first 24 h post-warming using ELISA.

**Statistical analysis**

Statistical analyses were performed by one-way ANOVA using Excel software. Each experiment to assess ELS recovery (viability, viable cell numbers, and function) was performed with five replicates and data are presented in Tables 1, 2, and 3 as the mean of these replicates ± standard deviation.

Results

**Feasibility studies in cryovials**

Effect of cooling profile and ice nucleation temperature on ELS recovery. For scale up of the small-volume (0.5 mL) cryopreservation protocols it was necessary to examine the effects of a number of physical variables. Five different cooling profiles were examined (shown in Fig. 2A). ELS were processed, with or without cholesterol as an ice nucleator.

The recovery of ELS viability in post-warming cultures was dependent on the temperature of ice nucleation during cooling (Fig. 2B). When ice nucleation occurred at temperatures below $$-12^\circ \text{C}$$ (in the absence of cholesterol) the recoveries were $$\sim 40\%$$. However, at ice nucleation induced at temperatures $$>-8^\circ \text{C}$$ (in the presence of cholesterol), viability was typically greater than 90% on thawing. Recovery of ELS was most variable following the multi-step cooling protocol. These data suggest that providing efficient ice nucleation occurs, a linear cooling rate of $$-1^\circ \text{C}/\text{min}$$ could be used in the large volume freezer and that deviations from linearity, within the range of the two nonlinear profiles examined, would be tolerated.

**Ultrastructure in the frozen state.** CryoSEM of ELS in samples in which ice had either been nucleated in a controlled manner (using cholesterol, Fig. 4A, C, E) or allowed to occur spontaneously (Fig. 4B, D, F) revealed major differences in the structure of both ice and ELS. Where spontaneous ice nucleation occurred, a uniform fine ice crystal structure ($$<25 \mu \text{m}$$ diameter) was evident, as etched voids, across the sample (honeycomb structure, Fig. 4D). The outlines of spherical alginate beads are detectable (Fig. 4B, D), and were similar in size to the unfrozen alginate beads ($$\sim 500 \mu \text{m}$$ diameter), but any cellular structure was generally masked by the pattern of ice formation. In those instances where cells were apparent (Fig. 4F), ice voids were apparent between cells, but intracellular ice was not evident. In samples with controlled nucleation, alginate beads were indistinguishable (Fig. 4A). ELS were freeze-concentrated into large aggregates (Fig. 4C, E); the individual ELS appeared highly shrunken. Ice crystal voids were adjacent to the cell clusters, and the alginate and extracellular matrix itself appeared to be dehydrated. At higher magnification (Fig. 4E) the outlines of shrunken cells were distinguishable within ELS. Any cellular material appeared granular, while freeze-concentrated alginate and CPA appeared smooth by comparison.

Freeze substitution of ELS within the induced ice-nucleated sample revealed shrunken cells with densely packed cytoplasm in which it was difficult to differentiate intracellular structures (Fig. 5A). At higher magnification, some cell membrane-like material could be seen but it was difficult to distinguish further. Many clear “shrinkage spaces” were evident. Following spontaneous ice nucleation cells did not appear so shrunken (Fig. 5B) and at higher magnification (Fig. 5D) intracellular organelles, such as mitochondria, were identifiable and there were few “shrinkage spaces.” Intracellular ice was not apparent in any samples, but following spontaneous nucleation intercellular ice had formed within cell clumps.

**FIG. 3.** Cooling profiles used for direct comparison of ELS recovery in small and large volumes. Three different cooling profiles were used to cool ELS in 1.8 mL cryovials using the EF600 and in 200 mL cryobags using the VIA Freeze to $$-100^\circ \text{C}$$ in parallel. A simple linear rate (A) was compared with nonlinear profiles (B, C). In large volumes, heat transfer occurs more slowly as a result of the increased mass. These nonlinear profiles were utilized as these are a more accurate representation of cooling profiles that would be experienced by ELS cooled in large volumes, where heat transfer would be altered compared with ELS cooled in small volumes. They were derived using mathematical modeling.19
Effect of reduced CPA volume on ELS recovery. ELS viability following a linear rate of cooling with cholesterol as ice nucleant was high with no trend toward reduced viability by decreasing the ratio of ELS to CPA, even at the highest cell density (∼30×10^6/mL). In contrast, lower viable cell numbers and total AFP secretion suggested that decreasing the volume of CPA was detrimental. However, normalized AFP secretion was unaffected by reducing the ELS:CPA ratio (Table 1). These data suggest that CPA volume, after a sufficient equilibration period, may be reduced during large-volume experiments with limited effects on ELS recovery; this simplifies application of large-volume cooling.

FIG. 4. Cryoscanning electron microscopy of fractured cryovials after cooling at a linear rate of 1°C/min. Ultrastructure resulting from controlled ice nucleation (A, C, E) is compared to spontaneous ice nucleation (B, D, F). In all samples the spaces originally occupied by ice crystals are revealed as voids following sublimation of ice. In figures (B, D) sectioned alginate beads that are ∼500 μm in diameter are outlined. In (C, E, F), cell clusters (c), ice voids (i), and smooth freeze concentrated alginate and cryoprotectant (CPA) (*) have been labeled. Scale bars on (A, B) 1 mm, on (C, D) 200 μm, and on (E, F) 20 μm.

FIG. 5. Freeze substitution of fractured cryovials after cooling at a linear rate of 1°C/min. Ultrastructure resulting from controlled ice nucleation (A, C) is compared with spontaneous ice nucleation (B, D). In spontaneously nucleated samples, the spaces originally occupied by ice crystals are revealed as voids following sublimation of ice, and can be seen throughout the ELS structure. These ice voids are absent within cholesterol-nucleated ELS, although there is evidence of shrinkage spaces. At higher magnification, it is difficult to distinguish cell organelles in cholesterol-nucleated ELS due to the extreme cell dehydration during cooling. Conversely, organelles can be seen in spontaneously nucleated ELS. Cellular material (c), ice voids (i), cell membrane (cm), extracellular matrix (ecm), mitochondria (m) shrinkage spaces (s), and alginate (*) have been labeled. Scale bars on (A, B) 2 μm and on (C, D) 500 nm.
Effect of warming conditions on ELS recovery. Following linear cooling at −1°C/min the recovery of ELS in cryovials was adversely affected by the time taken for warming (Table 2). Maximum recoveries were observed following rapid warming although the effect on viability was minor, with viabilities >90% for all thawed ELS at 24h post-warming.

However, both viable cell numbers and function were more affected by slower warming. Viable cell numbers decreased to 47%, 53%, 79%, and 82% cf. those of unfrozen controls when thawed using 4°C air (p<0.005), 20°C air (p<0.005), 20°C water (p<0.01), and 37°C water (p<0.01) respectively. Similarly, AFP secretion decreased to 37%, 43%, 49% and 57% cf. those of unfrozen controls when thawed using 4°C air (p<0.01), 20°C air (p<0.01), 20°C water (p<0.01) and 37°C water (p<0.05) respectively. These data suggest that rapid warming is crucial to ELS recovery.

Direct comparison of ELS cryopreservation in small volumes in cryovials with large volumes in cryobags

Measurement of cooling profiles using the VIA freeze. Temperature profiles from three different locations in CryoMACS bags containing cell-free alginate beads equilibrated with CPA are presented in Figure 6A and B along with process parameters of the VIA Freeze. Data are shown for a programmed linear cooling rate from +4°C to −100°C.

The measured temperature of the sample plate closely followed the set point (programme) temperature and was mirrored in a uniform way within the bag until ice nucleation occurred. Following ice nucleation and the presence of cholesterol, at a plate temperature of −7.9°C at a temperature in the fluid at the bottom of the bag of −5.4°C, there was a minor warming of the sample plate. To maintain the programmed cooling profile, a feedback loop increased the electrical power to the VIA Freeze, which then stabilized at a temperature within the range of ice nucleation. When cooling had progressed to ≤−30°C and below throughout the sample, the required power input for the VIA Freeze reduced again to that recorded pre ice nucleation. Temperature measurements within the bag (Fig. 6) show undercooking of the region in contact with the cold plate (Fig. 6A, dark gray line) while at the same time the rest of the sample was above the melting point of −4.5°C (Fig. 6A, mid- and light-gray lines). Ice nucleation occurred at the cold wall and heat was extracted as the ice front developed, shown by increased power consumption by the Stirling motors. In this configuration only a small region within the sample in contact with the cold wall was under cooled, and ice propagated through the bulk of sample with no localized undercooling.

Comparison of ELS recovery following cooling in cryobags using three different cooling profiles. There were no statistically significant differences in viabilities of ELS cryopreserved in cryobags using the three different cooling profiles (Table 3) (p>0.05). However, there were significant differences in viable cell numbers. ELS cryopreserved using Profile B showed significantly improved viable cell numbers in post-thaw culture when compared with ELS cryopreserved using either profile A (p<0.01) and profile C (p<0.05). Furthermore, function of ELS cryopreserved in cryobags using Profile A was significantly improved (p<0.005) cf. ELS cryopreserved using Profile C. Profile B also resulted in significantly improved function cf. Profile C (p<0.05).

Comparison of ELS recovery following cooling in either cryovials or cryobags. Samples were cooled using the profiles described in Figure 3, either in bags on the VIA Freeze or in cryovials on the EP600. The measured time for warming a bag containing 200 mL of alginate beads (cell free) from storage to 0°C in a 37°C water bath was ~2 min (c.f. 1.75 min in cryovials, Table 2).

ELS recoveries were assessed 24h post-warming and compared to an unfrozen control at equivalent time point. Using Profiles A or B (Fig. 3), there were no statistically significant differences in recovery (viability, viable cell number, or function) when ELS were cryopreserved in either cryovials or CryoMACS bags (Table 3). However, following Profile C (Fig. 3), ELS recovered from CryoMACS bags displayed greater viable cell numbers (p<0.005) and function (p<0.005) than ELS cryopreserved in cryovials (Table 3).
Discussion

We have previously described that ELS possess many useful synthetic and detoxification functions that could be utilized in the treatment of acute liver failure.\textsuperscript{2,14–17} Further, we have previously described that it is possible to cryopreserve ELS using both conventional liquid nitrogen and nitrogen-free CRFs.\textsuperscript{16,17} This work goes beyond this and a cryopreservation protocol developed for small volumes (0.5 mL) was successfully scaled up to large volumes (~200 mL) in a liquid nitrogen-free CRF, and a number of modifications to the small-scale processes were investigated. The Via Freeze CRF allowed accurate control of the rate of cooling to ~100°C, and has potential in processing large volumes of cells within clean room facilities, avoiding the issues associated with the use of liquid nitrogen-based systems. End temperatures of around ~90°C are sufficiently close to the glass transition range for this type of CPA mixture (typically around ~110°C\textsuperscript{20}) to allow safe transfer below ~150°C for storage, supported by the fact that the EF600 technology performed equally well compared with a conventional liquid nitrogen CRF in our previous study.\textsuperscript{17} Although in this study, samples were stored in the vapor phase of liquid nitrogen, Stirling cryocoolers capable of maintaining temperatures below ~150°C exist and could be used to avoid liquid nitrogen entirely during the cryopreservation process.

More importantly, in the context of standard cryopreservation protocols, the data generated during feedback power monitoring of the VIA Freeze may be used to confirm that ice nucleation has been successful as detectable power output is upregulated to compensate for latent heat release following ice nucleation. For example, for cells in bags, the absence of any voltage spikes at temperatures below a plate temperature of ~12°C would indicate that ice nucleation had been successful and that the sample viability should be high on warming. However, if a power-input spike was observed at lower plate temperatures, then controlled ice nucleation did not take place and significant undercooling had occurred, predictive of low survival and poor post-warming function. This may be both a valuable tool for future monitoring of cryopreservation protocols for quality control purposes in general, and active control of specific freezing processes allowing automatic cooling profile modification following ice nucleation to achieve beneficial nonlinear profiles.\textsuperscript{12,19}

The multi-step protocol previously used with small volumes\textsuperscript{16} was not essential; provided that efficient controlled ice nucleation occurred, simplified linear cooling rates were as effective (Table 3). The response of ELS to different ice nucleation temperatures demonstrates that as the extent of undercooling increases, viability post-cryopreservation decreases. CryoSEM and freeze substitution showed that controlled ice nucleation ensures significant cell shrinkage during cooling (Figs. 4 and 5). The intracellular “shrinkage spaces” have been reported elsewhere\textsuperscript{18} and are probably artefacts associated with efficient chemical fixation of the dehydrated sample (Fig. 5). In ELS that experienced extreme undercooling before ice nucleation occurred, there was little cell shrinkage (Fig. 4B), intracellular ice was not apparent, and the cells exhibited what might be classed as more “normal” morphology. Cellular dehydration occurs in response to the increased extracellular solute concentration that arises during ice formation as solutes are excluded from the ice lattice. During spontaneous ice nucleation, cells are unable to dehydrate, as ice formation is too rapid to allow dehydration within the short time frame. Conversely, during controlled nucleation, ice formation is slower, which enables cells to dehydrate. Following spontaneous ice nucleation, intercellular ice formed (Figs. 4F and 5B). This was not observed in samples in which controlled ice nucleation occurred and may be a stress that results in cell injury. While visually counterintuitive, our data showed that functional recoveries were lower when the ELS were more identifiable as structural entities (Fig. 4B vs. A), which agrees with other studies.\textsuperscript{21,22} This may reflect the importance of extreme dehydration for successful recovery from the cryopreservation process.

Stochastic ice nucleation during cooling modifies a number of physical processes within the freeze-concentrated matrix and any cells present will experience differing microenvironments. In particular, in samples with controlled ice nucleation the calculated diffusion distance within the freeze concentrated matrix is significantly larger than that following spontaneous ice nucleation.\textsuperscript{13} Effects on cell dehydration of controlled and spontaneous ice nucleation have previously been confirmed using Fourier transform infrared spectroscopy of mammalian cell lines\textsuperscript{23,24} and horse spermatozoa\textsuperscript{25} and it has been shown that cell dehydration is required to avoid lethal intracellular ice formation.

A second aim of this study was to reduce the amount of “excess” CPA volume processed. This is not trivial because, especially at scale up, this largely aqueous mass significantly contributes to the energy required to be removed during controlled cooling, and impacts on the ability to control the temperature profile throughout the entire sample. Similarly during recovery, excess CPA will limit the rate of warming, which is known to influence cell recovery. When ELS were equilibrated with CPA they could be frozen with little excess CPA and retain high viability and function. With ELS, the cell densities, (even with no “excess” CPA) were not high (~3 × 10^7/mL). In past studies, single cell suspensions, cryopreserved at high cell densities (equivalent to low CPA/biomass volume ratios), underwent significant damage, the so-called “cell packing” effect,\textsuperscript{26,27} but the cell densities were much higher than used here.

As ELS are encapsulated within alginate, it may be expected that the alginate itself offers some protection to the spheroids during cryopreservation. Polymers such as hydroxyl-ethyl starch can contribute toward cryoprotective effects in other systems\textsuperscript{28} and this has been attributed to increasing the viscosity, and modifying the water-ice transition.\textsuperscript{29} A similar argument has been proposed for alginate.\textsuperscript{30} However, in the large majority of cases (including our current work), cell-permeating CPAs are still required. It was clear from freeze-fracture studies (Fig. 4) that ice crystals grew throughout the alginate microspheres, although the control of ice nucleation appeared to result in larger ice crystals. Thus, any cryoprotection afforded by the alginate may result from complex interactions between polymer distribution and the biophysical events of a particular cryopreservation protocol.

Cell losses were observed when ELS of high densities were cryopreserved in small volumes; this could have
resulted from handling issues (such as adherence of beads inside tubes or pipettes). However, this was not seen during large-scale cryopreservation in bags.

In this initial study the identified optimal nonlinear profile was similar to that previously employed with cell clusters of human embryonic stem cells. In this profile (Fig. 3, Profile B) there is an extended holding period in the temperature zone following ice nucleation, which allows more time for osmotic equilibrium to be established between the cells and the external environment at high subzero temperatures. Ultrastructural studies (Figs. 4 and 5) demonstrated that significant cellular dehydration was protective; thus, osmotic equilibration of the cells with the partially frozen matrix during the extended holding period is one important component of this. However, when using another nonlinear profile (Fig. 3, Profile C), which further extended the period at high subzero temperatures after ice nucleation, a reduced recovery on thawing was observed, suggesting possible cytotoxic effects still occurring at high subzero temperatures. These are likely to contain components of both progressive osmotic injury and CPA toxicity. Further studies are needed to optimize, nonlinear profiles.

The data presented here demonstrate that it is possible to develop cryopreservation protocols in small volume (0.5 mL) samples, which can be scaled up to much larger volumes (200 mL).

A further step in scaling up cryobanking for ELS may require moving from a flexible bag (200 mL ELS) format to a rigid cylindrical cassette (2000 mL ELS). At these large volumes, with a concomitant reduction in the surface area to volume ratio of the sample, modeling suggests that heat transfer properties can significantly vary between different locations within the bulk three-dimensional volume as external cooling is applied with potential negative impact on successful cryopreservation. Both cooling and warming profiles will be affected. However, in the cryobag (thin film) format, heat transfer (and therefore cooling and warming rates) will not be significantly compromised compared with those achieved in cryovials, explaining why good results were obtained in both conditions during our current studies.

In translating cell therapies forward to the clinic and implementing essential cryobanking steps, there are several important considerations to achieve compliance with cGMP standards. These will include the selection of an optimized cryopreservation media and CPA mixtures, type and dimensions of containers, use of a liquid nitrogen-free CRF with appropriate methods for controlled ice nucleation, and detection of the nucleation process. All of these have been discussed in relation to the current study.

Acknowledgments

This work was funded by the Technology Strategy Board (project number 130328). The Wellcome Trust enabled fluorescence microscopy studies. We also thank Dr Jeremy Skepper, Department of Anatomy, University of Cambridge for electron microscopy.

Disclosure Statement


Address correspondence to:
Barry Fuller, PhD, DSc
University Department of Surgery
University College London Medical School
Royal Free Hospital Campus
Hampstead
London NW3 2QG
United Kingdom
E-mail: b.fuller@ucl.ac.uk

Received: September 30, 2013
Accepted: December 12, 2013
Online Publication Date: February 20, 2014